What is the current Price Target for the Aziyo Biologics Inc - Ordinary Shares - Class A stock?

The average Aziyo Biologics Inc - Ordinary Shares - Class A target price is $10.00. This is 180.90% higher than the current stock price. The highest price target is 180.90%, the lowest is 180.90%. 2 Analysts have issued a price target Aziyo Biologics Inc - Ordinary Shares - Class A 2025 .

What's going on with the Aziyo Biologics Inc - Ordinary Shares - Class A stock today?

The performance of Aziyo Biologics Inc - Ordinary Shares - Class A stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Aziyo Biologics Inc - Ordinary Shares - Class A Forecast, price target & analysts

Q: How high will the Aziyo Biologics Inc - Ordinary Shares - Class A stock rise?

No reliable answer can be given as to how high the Aziyo Biologics Inc - Ordinary Shares - Class A stock will rise. The performance of stocks, including the Aziyo Biologics Inc - Ordinary Shares - Class A stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

Q: Why did the Aziyo Biologics Inc - Ordinary Shares - Class A stock fall?

The decline in Aziyo Biologics Inc - Ordinary Shares - Class A stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

$3.56

7.05%

Nasdaq, Fri, Nov 15 2024

ISIN

US05479K1060

Symbol

AZYO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts Strategies

Aziyo Biologics Inc - Ordinary Shares - Class A Target price 2024 - Analyst rating & recommendation

Aziyo Biologics Inc - Ordinary Shares - Class A Classifications & Recommendation:

Buy

100%

Aziyo Biologics Inc - Ordinary Shares - Class A Price Target

Target Price	$10.00
Price	$3.56
Potential	180.90% register free of charge
Number of Estimates	2

	2 Analysts have issued a price target Aziyo Biologics Inc - Ordinary Shares - Class A 2025 . The average Aziyo Biologics Inc - Ordinary Shares - Class A target price is $10.00. This is 180.90% register free of charge higher than the current stock price. The highest price target is $10.00 180.90% register free of charge , the lowest is $10.00 180.90% register free of charge .
	A rating was issued by 2 analysts: 2 Analysts recommend Aziyo Biologics Inc - Ordinary Shares - Class A to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Aziyo Biologics Inc - Ordinary Shares - Class A stock has an average upside potential 2025 of 180.90% register free of charge . Most analysts recommend the Aziyo Biologics Inc - Ordinary Shares - Class A stock at Purchase.

Sales and Margin forecast 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '23	2024 Estimates
Revenue Million $	24.75	25.30
	49.68%	2.22%
EBITDA Margin	-68.81%	-52.17%
	48.39%	24.18%

2 Analysts have issued a sales forecast Aziyo Biologics Inc - Ordinary Shares - Class A 2024 . The average Aziyo Biologics Inc - Ordinary Shares - Class A sales estimate is

Unlock

. This is

Unlock

than the revenue of the last 12 months(TTM). The highest sales forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics:

2023	$24.8m	49.68%
2024	$25.3m 2.22% Unlock
2025	$33.5m 32.21% Unlock
2026	$70.4m 110.46% Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-2.40	-1.82
	0.84%	24.17%
P/E		negative
EV/Sales		5.11

2 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast for earnings per share. The average Aziyo Biologics Inc - Ordinary Shares - Class A <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	$-2.40	0.84%
2024	$-1.82 24.17% Unlock
2025	$-0.99 45.60% Unlock
2026	$-0.36 63.64% Unlock

Current	-1.42	118.46%
2024	-1.96 38.03% Unlock
2025	-3.60 83.67% Unlock
2026	-9.89 174.72% Unlock

Based on analysts' sales estimates for 2024, the Aziyo Biologics Inc - Ordinary Shares - Class A stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

Unlock

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of

Unlock

This results in the following potential growth metrics and future valuations:

Current	5.22	331.40%
2024	5.11 2.10% Unlock
2025	3.87 24.36% Unlock
2026	1.84 52.49% Unlock

Current	4.89	891.31%
2024	4.79 2.06% Unlock
2025	3.62 24.37% Unlock
2026	1.72 52.49% Unlock

Aziyo Biologics Inc - Ordinary Shares - Class A...

Discover more stocks with a high price target

Valneva 259.22%

CureVac N.V. 177.62%

Moderna 119.67%

Plug Power Inc. 90.78%

Bavarian Nordic 86.87%

BioNTech SE - ADR 36.45%

RWE 35.54%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now